Skip to main content
Premium Trial:

Request an Annual Quote

Richard DiMarchi, Thomas Daniel, Camron Nezhat

Premium

Richard DiMarchi has been appointed CEO and Thomas Daniel has become chief scientific officer of San Diego-based Ambrx. DiMarchi, one of the founders of Ambrx, was previously group vice president for biotechnology and product development at Lilly Research Laboratories, where he co-invented Humalog, the first biosynthetic protein approved for human use. He is a professor of chemistry at Indiana University and a member of Inproteo.

Daniel was previously vice president of research at Amgen, and was senior vice president of dis-covery research at Immunex before Amgen acquired it. He was also previously a professor of medicine and cell biology at Vanderbilt University and director of the Vanderbilt Center for Vascular Biology.


Camron Nezhat has been appointed to the scientific advisory board of CombiMatrix. Nezhat is a surgeon at Stanford University. He was the inventor of video laparoscopy, a now popular minimally invasive surgical technique for abdominal and pelvic surgery.

 

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.